VivoSeq
Other

Cornelia De Lange Syndrome

3

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Cornelia de Lange syndrome is an early-stage landscape with 3 programs across 2 companies. The most active players are Solvay Pharmaceuticals, Arbor Pharmaceuticals, Inc.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Solvay Pharmaceuticals

1 program

Phase 2A

Arbor Pharmaceuticals, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome
Not yet recruiting·JJohns Hopkins University·Phase 2·NCT04381897·10 enrolled
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment
Recruiting·UUniversity of Milan·Phase 2/3·NCT06789783·34 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)